Thrombotic Thrombocytopenic Purpura and Human T-Lymphotrophic Virus, Type 1 (HTLV-1)

Dixon, Andrew; Kwock, D W; Nakamura, J; Yanagihara, Eugene; Saiki, Stanley M.; Bodner, Anne J.; Alexander, Steven S.

doi:10.7326/0003-4819-110-1-93

Cited by 16 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HTLV-I is the etiologic agent of both ATLL and TSP/HAM. There have been several reports attempting to correlate HTLV-I infection with various autoimmune diseases, such as Sjogren's syndrome (39, systemic lupus erythematosus (35,36), arthritis (37), thrombotic thrombocytopenic purpura (38), thyroiditis (39), amyotrophic lateral sclerosis (40), chronic inflammatory arthopathy (41), and multiple sclerosis (MS) (42,43). Recent reports indicate that MS is unlikely to be a manifestation of HTLV-I infection (44).…”

Section: Discussionmentioning

confidence: 99%

Identification of human t cell leukemia/lymphoma virus type i antibodies, dna, and protein in patients with polymyositis

Sherman

Amin

Rodgers‐Johnson³

et al. 1995

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To investigate a possible association between human T cell leukemidymphoma virus type I (HTLV-I) and polymyositis (PM).Methods. Sera and muscle biopsy samples from 9 Jamaican PM patients were compared with specimens from American HTLV-I-positive PM patients and normal controls. Sera were evaluated for HTLV antibodies by enzyme-linked immunosorbent assay and Western blot. The biopsy samples were analyzed for HTLV-YII DNA by polymerase chain reaction and were also immunohistochemically stained for HTLV gp46 envelope protein.Results. Seven of the 8 Jamaican PM patients from whom sera were available were HTLV-I seropositive. The muscle biopsies of all 9 Jamaican patients demonstrated severe lymphocytic infiltration, cellular degeneration, myofiber atrophy, and fibrosis. Each muscle biopsy specimen contained HTLV-I DNA. Two of 6 samples demonstrated intense staining for HTLV-I gp46 in many of the invading mononuclear cells and weak staining for HTLV-I gp46 in many of the invading mononuclear cells and weak staining in the adjacent Supported in part by NIH grants 5 UO1 AI-27658 and RO1

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of human t cell leukemia/lymphoma virus type i antibodies, dna, and protein in patients with polymyositis

Sherman

Amin

Rodgers‐Johnson³

et al. 1995

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…Fourteen cases of TTP have been reported in association with HIV infection, mainly in asymptomatic (10 of 14) patients [1][2][3][4][5][6]. One case was recently reported to be associated with HTLV-I [9].…”

Section: Discussionmentioning

confidence: 99%

Immunologic thrombocytopenia followed by thrombotic thrombocytopenic purpura in two HIV₁ patients

et al. 1991

View full text Add to dashboard Cite

Two homosexual HIV1-positive male patients with thrombotic thrombopenic purpura (TTP) were found to have past history of immune thrombocytopenia (ITP). The first patient had ITP 10 months prior to TTP and was successfully treated by splenectomy. The second patient had ITP 32 months before TTP. No specific treatment was given for his asymptomatic ITP. Association of HIV infection to TTP seems to be frequent. These two types of purpura have different pathogenic mechanisms but share a common altered immune response to antigenic challenge. The occurrence of ITP and TTP in HIV-positive patients may lead to errors in diagnosis and therapy.

show abstract

“…3 ). However, Dixon [ 156 ] reported the presence of thrombotic thrombocytopenic purpura (TTP) in patients with HTLV-1, and according to a review performed by Araujo et al [ 157 ], venous thrombosis appears to be a major complication of HTLV-associated myelopathy/tropical spastic paraparesis in wheelchair-bound patients, a neurodegenerative disease induced by HTLV-1. Additionally, according to Séne et al [ 158 ], ACAs, which have already been described as being frequently associated with viral infections and known to trigger coagulation and inflammatory signalling, are found to be highly prevalent in the acute phase of HTLV-1 infection.…”

Section: Viral Carcinogenesis and Vte Incidencementioning

confidence: 99%

Map of thrombogenesis in viral infections and viral-driven tumours

et al. 2023

View full text Add to dashboard Cite

Viruses are pathogenic agents responsible for approximately 10% of all human cancers and significantly contribute to the global cancer burden. Until now, eight viruses have been associated with the development of a broad range of malignancies, including solid and haematological tumours. Besides triggering and promoting oncogenesis, viral infections often go hand-in-hand with haemostatic changes, representing a potential risk factor for venous thromboembolism (VTE). Conversely, VTE is a cardiovascular condition that is particularly common among oncological patients, with a detrimental impact on patient prognosis. Despite an association between viral infections and coagulopathies, it is unclear whether viral-driven tumours have a different incidence and prognosis pattern of thromboembolism compared to non-viral-induced tumours. Thus, this review aims to analyse the existing evidence concerning the association of viruses and viral tumours with the occurrence of VTE. Except for hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infection, which are associated with a high risk of VTE, little evidence exists concerning the thrombogenic potential associated with oncoviruses. As for tumours that can be induced by oncoviruses, four levels of VTE risk are observed, with hepatocellular carcinoma (HCC) and gastric carcinoma (GC) associated with the highest risk and nasopharyngeal carcinoma (NPC) associated with the lowest risk. Unfortunately, the incidence of cancer-related VTE according to tumour aetiology is unknown. Given the negative impact of VTE in oncological patients, research is required to better understand the mechanisms underlying blood hypercoagulability in viral-driven tumours to improve VTE management and prognosis assessment in patients diagnosed with these tumours.

show abstract

Thrombotic Thrombocytopenic Purpura and Human T-Lymphotrophic Virus, Type 1 (HTLV-1)

Cited by 16 publications

References 5 publications

Identification of human t cell leukemia/lymphoma virus type i antibodies, dna, and protein in patients with polymyositis

Identification of human t cell leukemia/lymphoma virus type i antibodies, dna, and protein in patients with polymyositis

Immunologic thrombocytopenia followed by thrombotic thrombocytopenic purpura in two HIV₁ patients

Map of thrombogenesis in viral infections and viral-driven tumours

Contact Info

Product

Resources

About

Thrombotic Thrombocytopenic Purpura and Human T-Lymphotrophic Virus, Type 1 (HTLV-1)

Cited by 16 publications

References 5 publications

Identification of human t cell leukemia/lymphoma virus type i antibodies, dna, and protein in patients with polymyositis

Identification of human t cell leukemia/lymphoma virus type i antibodies, dna, and protein in patients with polymyositis

Immunologic thrombocytopenia followed by thrombotic thrombocytopenic purpura in two HIV1 patients

Map of thrombogenesis in viral infections and viral-driven tumours

Contact Info

Product

Resources

About

Immunologic thrombocytopenia followed by thrombotic thrombocytopenic purpura in two HIV₁ patients